Wealthspire Advisors (New York)’s Annovis Bio ANVS Stock Holding History

Wealthspire Advisors (New York)’s Portfolio ANVS Stock Details ANVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$44.6K	Hold	20,000	–	–	﹤0.01%	909
2025 Q4	$69.2K	Buy	20,000 +10,000	+100%	+$30.1K	﹤0.01%	1013
2025 Q3	$20.7K	Hold	10,000	–	–	﹤0.01%	1668
2025 Q2	$21.7K	Sell	10,000 -50	-0.5%	-$99	﹤0.01%	842
2025 Q1	$15.1K	Hold	10,050	–	–	﹤0.01%	784
2024 Q4	$50.6K	Buy	10,050 +50	+0.5%	+$362	﹤0.01%	774
2024 Q3	$80.6K	Hold	10,000	–	–	﹤0.01%	729
2024 Q2	$57.6K	Hold	10,000	–	–	﹤0.01%	648
2024 Q1	$119K	Sell	10,000 -990	-9%	-$10.8K	﹤0.01%	622
2023 Q4	$206K	Buy	10,990 +990	+10%	+$8.78K	﹤0.01%	613
2023 Q3	$94.9K	Hold	10,000	–	–	﹤0.01%	580
2023 Q2	$143K	Hold	10,000	–	–	﹤0.01%	542
2023 Q1	$154K	Buy	+10,000	New	+$161K	﹤0.01%	510
2021 Q4	–	Sell	-7,500	Closed	-$238K	–	540
2021 Q3	$238K	Buy	7,500 +2,500	+50%	+$144K	﹤0.01%	505
2021 Q2	$428K	Sell	5,000 -5,000	-50%	-$231K	0.01%	240
2021 Q1	$279K	Buy	+10,000	New	+$214K	0.01%	572

Other funds holding ANVS

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Wealthspire Advisors (New York)'s ANVS Position: Q1 2026 in Review

Wealthspire Advisors (New York) held its Annovis Bio (ANVS) position steady in Q1 2026 at 20,000 shares worth $44.6K. The position accounts for ﹤0.01% of the portfolio, ranked #909.

Wealthspire Advisors (New York) first reported a position in ANVS in Q1 2021 and has held it in 16 quarters since. The position peaked at $428K in Q2 2021. 56 funds tracked by Wall St. Rank hold ANVS as of Q1 2026.

Wealthspire Advisors (New York) held 20,000 shares of Annovis Bio worth $44.6K as of Q1 2026.
Wealthspire Advisors (New York) left its Annovis Bio share count unchanged in Q1 2026.
Annovis Bio made up ﹤0.01% of Wealthspire Advisors (New York)'s portfolio in Q1 2026, its #909 holding.
Wealthspire Advisors (New York) first reported a position in Annovis Bio in Q1 2021 and has held it in 16 quarters since.
Wealthspire Advisors (New York)'s Annovis Bio position peaked at $428K in Q2 2021.
56 funds tracked by Wall St. Rank held Annovis Bio as of Q1 2026.

Based on Wealthspire Advisors (New York)'s 13F filing for Q1 2026, filed 1 May 2026.